Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants.

Background: Little is known about physiological anticoagulation effects via antithrombin III (AT III) and protein C/S (PC/PS) in patients using new oral anticoagulants (NOACs).

Methods: We evaluated 120 consecutive patients with non-valvular atrial fibrillation (AF) receiving NOACs. Patients were randomly divided into three groups: a dabigatran group (DG, =40), a rivaroxaban group (RG, =40) or an apixaban group (AG, =40).